No Data
Hongkong Tigermed Co., Limited increased its shareholding of Frontage Holdings (01521) by 6 million shares at a price of 0.807 Hong Kong dollars per share.
On October 31st, Hongkong Tigermed Co., Limited increased its shareholding of frontage (01521) by 6 million shares, priced at 0.807 Hong Kong dollars per share, with a total amount of 4.842 million Hong Kong dollars.
Zheshang: Innovative drugs, blood products and other fields may benefit from the slow recovery on the demand side.
Zheshang released research reports stating that the transition of pharmaceutical new and old kinetic energy will continue in the next stage, with innovative drugs, supply cleaning or better framework in areas such as innovative drug supporting industry chain, large infusion, anesthetic drugs, blood products, pharmaceutical circulation, traditional chinese medicine OTC, benefiting from the slow recovery on the demand side, potentially with better growth prospects.
Tigermed (300347.SZ): has repurchased 0.42% of the shares accumulated.
According to the announcement by Tigermed (300347.SZ) on November 5th, until October 31, 2024, the company repurchased a total of 3,655,200 shares through the special securities account for share repurchase using centralized bidding trading method, accounting for 0.4226% of the total share capital and 0.4927% of the total A-share capital. The highest fill price was 55.30 yuan/share, the lowest fill price was 48.17 yuan/share, and the total fill amount was 0.191 billion yuan (excluding trading fees).
Abnormal movements | The CRO concept is generally rising, with medical insurance negotiations supporting innovative drugs. Global biomedical financing will rebound in an environment of interest rate cuts.
The concept of CRO is generally on the rise. As of the time of publication, Asymchem Laboratories rose by 4.95%, to 59.4 Hong Kong dollars; Tigermed rose by 5.21%, to 38.35 Hong Kong dollars; WuXi AppTec rose by 3.69%, to 53.4 Hong Kong dollars.
Tigermed (300347): Revenue has improved compared to the previous month. Continuous improvement in new signed orders.
Revenue improved compared to the previous period, with new orders continuing to improve. In the first three quarters of 2024, the company achieved revenue of 5.068 billion yuan, a year-on-year decrease of 10.32%; net income attributable to the mother was 0.813 billion yuan, a year-on-year decrease of 56.72%; excluding non-recurring items.
tigermed (300347): Short-term multiple factors disturbances, bullish on performance improvement trend
The core view of the company's 24 Q1-3 revenue and profit performance has been short-term disturbed by multiple factors. In Q3, the revenue side increased steadily on a quarter-on-quarter basis, while the profit side fluctuated due to the company's large amount of deposit income financial recognition method and exchange gains and losses.
No Data
No Data